Travere Therapeutics Inc (TVTX) shares reached a 52-week high of 66.35 USD on Tuesday, trading within 1% of the peak. The biopharmaceutical company’s stock has rallied 112% over the past six months, 69% year-to-date, and 265.46% over the past year, driven by strong commercial performance of its kidney disease drug FILSPARI.
Second-quarter 2026 revenue totaled 169.6 million USD, exceeding Wall Street’s forecast of 160.66 million USD. U.S. net product sales accounted for 161.4 million USD of the total, while cash, equivalents, and marketable securities stood at approximately 489.2 million USD at quarter-end. FILSPARI sales surged 96% year-over-year to 141.1 million USD, reflecting the drug’s expanded use for both IgA nephropathy and the newly launched indication in FSGS.
The company reported 2,012 start forms for FILSPARI in Q2, up from 993 in the prior quarter, signaling accelerating adoption. Analysts have responded with mixed views: Stifel raised its price target to 62 USD from 43 USD but maintained a Hold rating, while price targets across the Street range from 62 USD to 90 USD. InvestingPro analysis indicates the stock trades above fair value, placing it on the platform’s Most Overvalued list.
